Abstract: A polymerization inhibiting system includes a measuring apparatus, a supplying apparatus and a control apparatus. The measuring apparatus is configured to continuously measure a concentration of an oligomer that is included in at least one of a raw material containing monomer as a main component and an intermediate product from the raw material in a manufacturing process for producing a product from the raw material. The supplying apparatus is configured to supply a polymerization inhibitor in the manufacturing process. The control apparatus is configured to control a supply rate of the polymerization inhibitor by the supplying apparatus, based on a measurement result of the measurement made by the measuring apparatus.

Abstract: The invention provides a reactor comprising a reaction chamber having a catalytic surface in contact with reactants in said chamber, and a source for passing electrical current through said catalytic surface. The reactor can be used for dehydrohalogentation reactions, such as dehydrochlorination of HCFC-244bb to HFO-1234yf and for reactions where zero valent metals are employed for catalysis. The invention further provides a process to prepare HFO-1234yf from HCFC-244bb using an electrically heated reaction chamber.

Abstract: There is provided an economically advantageous manufacturing method capable of efficiently obtaining 1-chloro-2,3,3,3-tetrafluoropropene by using 1,2-dichloro-2,3,3,3-tetrafluoropropane as a raw material. A manufacturing method of 1-chloro-2,3,3,3-tetrafluoropropene is characterized in that it includes subjecting 1,2-dichloro-2,3,3,3-tetrafluoropropane to a dehydrochlorination reaction in a liquid phase in a presence of a base.

Abstract: A process for producing a main (hydro)halocarbon compound, including the formation of a mixture of compounds including hydrogen fluoride, Z-3,3,3-trifluoro-1-chloropropene and one or more other (hydro)halocarbon compounds, distillation of this mixture making it possible to collect, firstly, an azeotropic composition, and, secondly, at least one of the compounds of the mixture. The (hydro) halocarbon compounds are preferably selected among tetrachlorofluoropropanes, trichlorodifluoropropanes, dichlorotrifluoropropanes, chlorotetrafluoropropanes, pentafluoropropanes, dichlorodifluoropropenes, chlorotrifluoropropenes and tetrafluoropropenes.

Abstract: A process for the production of glycols is provided, the process comprising contacting a saccharide-containing feedstock with hydrogen in the presence of a catalyst composition and a solvent, wherein the solvent comprises water and at least 25% by weight, based on the total weight of the solvent, of one or more alcohols selected from a C1 to C6 alcohol, a C1 to C6 polyalcohol, and a combination thereof.

Abstract: Utilizing the common knowledge formula for creation of methanol CO2+3H2?CH3OH+H2O; for each mole of carbon dioxide, three moles of hydrogen are needed to produce one equivalent unit of methanol. Therefore, it is possible to produce over one-half gallon of methanol from one kilogram of carbon dioxide. Combining the two gases and producing methanol can be accomplished under high pressure (about 3250 psi) and high temperature (750-degree Fahrenheit heat) without the presence of a catalyst. Throughout this process, auto-ignition for methanol is 867-degree Fahrenheit (or 464° C.) and auto-ignition for hydrogen is 932-degree Fahrenheit (or 500° C.). After mixing two gases in the mixing chamber, the result is methanol and water. The first step in this stage is to cool the substance by way of cooling tower and pressure lowering tank. Next is a separation process to separate methanol and water. By cooling the substance\mixture about 28.

Abstract: The present invention pertains to novel octahydro-indene compounds and their unexpected advantageous use thereof in enhancing, improving or modifying the fragrance of perfumes, colognes, toilet waters, fabric care products, personal products, and the like.

Abstract: Disclosed herein, inter alia, are compositions and methods useful for treating non-alcoholic fatty liver diseases.

Abstract: The present disclosure relates to inhibitors of herpesvirus nucleic acid metabolism and inhibitors of Hepatitis B virus. Also provided are methods of treatment using these agents.

Abstract: Methods for total chemical synthesis of Resolvin E1 (RvE1) include Wittig reaction of two compounds having hydroxyl protecting group in the presence of a strong base, removal of the hydroxyl-protecting groups with a deprotecting reagent to produce a compound having an ester group, and hydrolysis of the ester group to obtain RvE1

Abstract: The invention relates to a process for the production of 1,6-difunctionalized hexane derivatives from 1,3-diunsaturated hydrocarbons, preferably butadiene, wherein a hydroformylation with carbon monoxide and hydrogen is performed in the presence of an at least dihydric alkanol and during the hydroformylation the temperature is increased. The reaction yields the acetals of the 1,6-hexanedial derivatives which are isolated and further reacted to obtain the desired 1,6-difunctionalized hexane derivatives, in particular 1,6-hexanediamine, 1,6-hexanediol and adipic acid.

Abstract: A process for the purification of levulinic acid including the following steps: a. providing a composition 1, comprising at least 75 wt. % of levulinic acid; b. cooling composition 1 to at least one temperature Tc, wherein Tc is a temperature in the range 1.23*(W1)?104.5?Tc (° C.)?1.23*(W1)?89.5, wherein W1 is the weight % of levulinic acid in composition 1, to obtain a cooled composition 1; c. performing melt crystallization of composition 1 including the steps of: i. bringing the cooled composition 1 into contact with levulinic acid crystal seeds, ii. allowing the levulinic acid in composition 1 to crystallize at at least one temperature Tc to obtain crystals 1 and liquid 1, and iii. draining of liquid 1; d. optionally, treating crystals 1, after draining of liquid 1, by sweating, according to the following steps: i. heating the crystals 1 at a temperature between 5 and 40° C. to obtain crystals 2 and liquid 2, and ii. draining of liquid 2; e.

Abstract: The invention provides compositions and methods for ameliorating, treating, reversing or preventing pathology or inflammation in the central nervous system (CNS), or the brain, caused or mediated by NFkB, IL-6, IL-6-R, NADPH oxidase (Nox), and/or superoxide and/or hydrogen peroxide production by a NADPH oxidase, including for example ameliorating, treating, reversing or preventing schizophrenia, psychosis, delirium, e.g., post-operative delirium, drug-induced psychosis, psychotic features associated with frailty syndrome (FS), aging, depression, dementias; traumatic war neurosis, post traumatic stress disorder (PTSD) or post-traumatic stress syndrome (PTSS), Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's Disease), and/or Multiple Sclerosis (MS). The invention also provides methods for purifying a C60 fullerene, C3 (tris malonic acid C60) or malonic acid derivatives.

Abstract: This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 ?m to about 90 ?m, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

Abstract: A process for purifying methyl methacrylate. The method comprises: (a) feeding a product mixture comprising methyl methacrylate, methanol, water and oligomers of methyl methacrylate to a divided section of a distillation column comprising a dividing wall; (b) removing an overhead stream and a bottoms stream from the distillation column, and removing a middle side draw stream from the distillation column; wherein the crude product enters the dividing wall distillation column in a divided section on an opposing side of the dividing wall from the middle side draw stream; and (c) removing an upper side draw stream from a point above the dividing wall and below the top of the distillation column, separating a portion of water from the upper side draw stream to produce a dewatered upper side draw stream and returning the dewatered upper side draw stream to the distillation column.

Abstract: Compositions and methods for inhibiting, treating, and/or preventing fatty acid metabolism disorders, particularly fatty acid oxidation disorders, in a subject are provided.

Abstract: A nickel diatomaceous earth catalyst having a weight loss rate measured by hydrogen-TG at 400 to 600° C. of 0.05 to 2.0%.

Abstract: Processes are disclosed for preparing a diamine/dicarboxylic acid salt, wherein the dicarboxylic acid includes an aromatic dicarboxylic acid and is provided in a powder form. The diamine is provided in a liquid form gradually dosed to the dicarboxylic acid powder, while keeping the dicarboxylic acid powder in constant movement; the processing temperature is above 0° C. and below the boiling temperature of the diamine and the melting temperature of the acid and the salt, and the reaction mixture comprises at most 5 wt. % of water. An anhydrous diamine/dicarboxylic acid salts obtained by the process are also provided.

Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.

Abstract: ?-Substituted ?-amino acids, ?-substituted ?-amino acid derivatives, and ?-substituted ?-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

Abstract: A catheter assembly includes an elongated catheter shaft, a magnetic sensor, and one or more wires. The elongated catheter shaft has a shaft proximal end and a shaft distal end, and the magnetic sensor includes a coil having a coil proximal end and a coil distal end that is situated toward or at the shaft distal end. The one or more wires extend through the elongated catheter shaft and are situated adjacent the magnetic sensor. Each of the one or more wires is electrically coupled to the coil at the coil distal end.

Abstract: This invention relates to a wax composition comprising a plurality of fatty acid amide compounds having the Formula (I): where R1, R2, n1, n2, m1, and m2 are as described herein. This invention also relates to a wax composition comprising: a) one or more fatty acid amide compounds having the Formula (II): and b) one or more fatty acid amide compounds having the Formula (III): where R1, R2, n1, and n2 are as described herein. This invention also relates to a fatty acid amide compound having the Formula (I) and a process for preparing a compound of Formula (I).

Abstract: Here described are compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including these compounds which are useful for the targeting and delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.

Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

Abstract: The invention relates to a method for preparing an aromatic polyisocyanate in an isocyanate plant comprising a reaction section for a phosgenation reaction, wherein a primary aromatic amine is reacted with phosgene compounds in a reaction section to obtain an isocyanate comprising reaction product and wherein CO2 concentration in the gases coming from the reaction section is measured and analyzed, and wherein the conditions in the phosgenation reaction are adjusted in case the CO2 concentration in the gases coming from the reaction section is higher than a background CO2 concentration.

Abstract: A process is provided for preparation of (R)—N-Boc biphenyl alaninol. It provides a preparation process for a compound outlined as compound 4, which includes these operations: in one of the alcohol solvents, asymmetric hydrogenation of 5 in the presence of [Rh(Duanphos)(X)]Y and hydrogen to provide compound 4. Here “Duanphos” is (Rc,Sp)-Duanphos or (Sc,Rp)-Duanphos; X is NBD or/and COD; Y is one or more of BF4, PF6, SbF6. This process has a lot of advantages, such as low cost, safe operation, less pollution and high yield. The product was obtained in >99% purity and ee which is suitable to scale up in industrial scale.

Abstract: Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.

Abstract: Provided is a method for producing a polythiol compound, including obtaining one or more polythiol compounds selected from the group consisting of a polythiol compound represented by Formula (3), a polythiol compound represented by Formula (4), and a polythiol compound represented by Formula (5) through steps including: reacting 2-mercaptoethanol with an epihalohydrin in an amount of 1.00 equivalent or more and 1.25 equivalent or less with respect to the 2-mercaptoethanol to obtain a polyol compound represented by Formula (1); and reacting the polyol compound represented by Formula (1) with an alkali metal sulfide in an amount of 1.04 equivalent or more and 1.25 equivalent or less with respect to the 2-mercaptoethanol to obtain a polyol compound represented by Formula (2).

Abstract: The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.

Abstract: The present invention relates to Saroglitazar free acid of Formula (IA) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, stereoisomers, tautomers, analogs and derivatives thereof. The present invention also provides an amorphous form of saroglitazar free acid and processes of preparation thereof. The present invention also provides pharmaceutical composition comprising an amorphous form saroglitazar magnesium.

Abstract: The present invention relates to Saroglitazar free acid of Formula (IA) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, stereoisomers, tautomers, analogs and derivatives thereof. The present invention also provides an amorphous form of saroglitazar free acid and processes of preparation thereof. The present invention also provides pharmaceutical composition comprising an amorphous form saroglitazar magnesium.

Abstract: Long-term and high-density energy sources are described that utilize radioisotope batteries that provide a tritium (3H)-based direct energy conversion system. The beta radiation source is a nitroxide compound with a synthetic yield near 100%. The nitroxide compound can be molded into flexible films to cover multiple structures, and has a specific activity and gravimetric density (wt % 3H) comparable to that of tritiated hydrides. A carrier system based on such tritiated nitroxides can be scaled up without significant beta self-absorption, permitting the energy source to have higher specific volume power densities than current radioisotope batteries. Such a carrier can be applied directly to a semiconductor array (such as an integrated circuit) in order to provide electrical power or, alternatively, be prepared with a phosphor and applied to a photovoltaic cell.

Abstract: The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and use thereof. The compound represented by the Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof can be effectively used in the prevention or treatment of pains, for example, acute pain, chronic pain, pain from nervous disease, postoperative pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, paroxysmal extreme pain disorder (PEPD).

Abstract: Disclosed are methods for the preparation of Tecovirimat for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.

Abstract: The present invention discloses an organic electronic luminescent material, with the chemical formula (I). The compounds having the chemical formula (I) in the present invention have highly stable electron-withdrawing groups and electron-donating groups with stable chemical bonds between them but without a strong conjugation. With these features, the compounds with the formula (I) have high fluorescence quantum efficiency and excellent charge transport ability. These compounds are closer to the dark color of international standard, which is conducive to achieve full color displays with higher color purity.

Abstract: A new process for the preparation of fexofenadine and of related intermediates, which can be used in the preparation of fexofenadine, is provided.

Abstract: The present invention relates to novel processes for the preparation of substituted pyridyl-methylbenzamide derivatives of formula (I), in particular 2,6-dichloro-N-{[3-chloro-5-(trifluoromethyl)-2-pyridyl]methyl}benzamide (Fluopicolide), and for the catalytic hydrogenation of substituted cyanopyridine derivatives, in particular 3-chloro-2-cyano-5-trifluoromethylpyridine [=Py-CN] to the corresponding substituted 2-methylaminopyridine derivatives, in particular 2-aminomethyl-3-chloro-5-trifluoromethylpyridine [=Py-methylamine] or salts thereof in the presence of metal catalysts such as in particular palladium catalysts, catalytic modifiers and acids.

Abstract: A pyridine compound represented by formula (I), or an N-oxide thereof is provided, wherein the variable groups are as defined in the specification. The pyridine compound of formula has excellent control effects against harmful arthropods.

Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, O and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g.

Abstract: A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) represented by the formula (1): The water content is adjusted to a level of from 5 to 15%, and the crystal form is controlled to be crystal form A, thereby to obtain a drug substance excellent in stability.

Abstract: The present disclosure relates to a compound that has biocidal activity or is a precursor of a compound with biocidal activity. The compound comprises an N-halamine precursor, at least one quaternary ammonium and at least one coating-incorporation group (CIG). In some embodiments of the present disclosure, the compound may be incorporated into a coating formulation. The coating formulation comprises the compound and at least one further component. In some embodiments of the present disclosure, the CIG reacts with the further component of the coating formulation to incorporate the compound into the coating formulation. In some embodiments, the coating formulation comprises a polymer. In some embodiments, the CIG of the compound reacts with the further component to incorporate the compound into the polymer of the coating formulation. The coating formulation may be used to coat a substrate. The coated substrate may demonstrate biocidal activity or the potential for increased biocidal activity.

Abstract: The present invention discloses an etomidate derivative of Formula 1, or a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, a pharmaceutical composition and a kit comprising the same, as well as intermediates and methods for preparing the same, and use thereof. The etomidate derivative of the present invention not only has good anesthetic activity, rapid onset, and short duration of action, but also shows little inhibition to the secretion of corticosteroids in animals, and therefore has both favorable anesthetic effect and safety profiles.

Abstract: The present invention belongs to the pharmaceutical field, and relates to a preparation method for a series of benzimidazole derivatives, their pharmaceutical salts and pharmaceutically acceptable prodrugs, a pharmaceutical composition containing the derivatives, and the uses of the derivatives and pharmaceutical composition in the preparation of antigout drugs and in the treatment of related diseases.

Abstract: 1,2,3-triazolyl cyclohexanol derivatives have been disclosed and their use as ligands accelerating the copper(I)-catalyzed azide-alkyne cycloaddition and the zinc(II)-catalyzed azide-nitrile cycloaddition.

Abstract: The present invention relates to compounds of formula I wherein R1? is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tertbutyl, cyclopropyl or CF3; R3 is Cl, F, CF3, methyl, methoxy, isopropyl or cyclopropyl; R4 is hydrogen, methyl, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof for use in the treatment of schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

Abstract: Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.

Abstract: Disclosed herein, inter alia, are agents having antiviral activity and methods of use thereof.

Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined in the description. The compounds of formula (I) are inhibitors of the YAP/TAZ-TEAD interaction.

Abstract: The invention describes compounds that inhibit both HDAC and GSK3? (i.e., HDAC/GSK3? dual inhibitors). The invention further describes compositions containing these HDAC/GSK3? dual inhibitors, as well as methods and kits using these HDAC/GSK3? dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3? to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3?. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.